A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

@article{Lawitz2013AP2,
  title={A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.},
  author={Eric J. Lawitz and Fred P Poordad and Kris V. Kowdley and Daniel E. Cohen and Thomas J. Podsadecki and Sara Siggelkow and Lois Larsen and Rajeev R Menon and Gennadiy Koev and Rakesh L Tripathi and Tami J. Pilot-Matias and Barry Bernstein},
  journal={Journal of hepatology},
  year={2013},
  volume={59 1},
  pages={18-23}
}
BACKGROUND & AIMS ABT-450 (combined with low-dose ritonavir, ABT-450/r) is a potent HCV NS3 protease inhibitor, and ABT-072 is a non-nucleoside NS5B polymerase inhibitor. The goal of this study was to evaluate the safety, tolerability, and efficacy of the peginterferon-free combination of ABT-450/r and ABT-072 with ribavirin in treatment-naïve patients with IL28B CC genotype, infected with HCV genotype 1. METHODS This was a phase 2a, multicenter, open-label, single-arm study in 11 treatment… CONTINUE READING